201 related articles for article (PubMed ID: 20371696)
21. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.
Khoja L; Lorigan P; Zhou C; Lancashire M; Booth J; Cummings J; Califano R; Clack G; Hughes A; Dive C
J Invest Dermatol; 2013 Jun; 133(6):1582-90. PubMed ID: 23223143
[TBL] [Abstract][Full Text] [Related]
22. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma.
Lucci A; Hall CS; Patel SP; Narendran B; Bauldry JB; Royal RE; Karhade M; Upshaw JR; Wargo JA; Glitza IC; Wong MKK; Amaria RN; Tawbi HA; Diab A; Davies MA; Gershenwald JE; Lee JE; Hwu P; Ross MI
Clin Cancer Res; 2020 Apr; 26(8):1886-1895. PubMed ID: 32015020
[TBL] [Abstract][Full Text] [Related]
23. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method.
Arenberger P; Arenbergerova M; Gkalpakiotis S; Lippert J; Stribrna J; Kremen J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):56-64. PubMed ID: 18181974
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.
Palmieri G; Ascierto PA; Perrone F; Satriano SM; Ottaiano A; Daponte A; Napolitano M; Caracò C; Mozzillo N; Melucci MT; Cossu A; Tanda F; Gallo C; Satriano RA; Castello G
J Clin Oncol; 2003 Mar; 21(5):767-73. PubMed ID: 12610172
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
26. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Thiel E; Foerster MH; Keilholz U
Oncology; 2011; 80(1-2):57-62. PubMed ID: 21625180
[TBL] [Abstract][Full Text] [Related]
27. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon.
Mellado B; Del Carmen Vela M; Colomer D; Gutierrez L; Castel T; Quintó L; Fontanillas M; Reguart N; Domingo-Domènech JM; Montagut C; Estapé J; Gascón P
J Clin Oncol; 2002 Oct; 20(19):4032-9. PubMed ID: 12351601
[TBL] [Abstract][Full Text] [Related]
28. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
29. Circulating epithelial tumor cells as a prognostic tool for malignant melanoma.
Pachmann K; Willecke-Hochmuth R; Schneider K; Kaatz M
Melanoma Res; 2018 Feb; 28(1):37-43. PubMed ID: 29076925
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract][Full Text] [Related]
31. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.
Domingo-Domènech J; Molina R; Castel T; Montagut C; Puig S; Conill C; Martí R; Vera M; Auge JM; Malvehy J; Grau JJ; Gascon P; Mellado B
Oncology; 2005; 68(4-6):341-9. PubMed ID: 16020961
[TBL] [Abstract][Full Text] [Related]
32. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma.
Mocellin S; Del Fiore P; Guarnieri L; Scalerta R; Foletto M; Chiarion V; Pilati P; Nitti D; Lise M; Rossi CR
Int J Cancer; 2004 Sep; 111(5):741-5. PubMed ID: 15252844
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
[TBL] [Abstract][Full Text] [Related]
34. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
[TBL] [Abstract][Full Text] [Related]
35. Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.
Gray ES; Reid AL; Bowyer S; Calapre L; Siew K; Pearce R; Cowell L; Frank MH; Millward M; Ziman M
J Invest Dermatol; 2015 Aug; 135(8):2040-2048. PubMed ID: 25830652
[TBL] [Abstract][Full Text] [Related]
36. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
37. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis.
Mellado B; Colomer D; Castel T; Muñoz M; Carballo E; Galán M; Mascaró JM; Vives-Corrons JL; Grau JJ; Estapé J
J Clin Oncol; 1996 Jul; 14(7):2091-7. PubMed ID: 8683241
[TBL] [Abstract][Full Text] [Related]
38. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma.
De Giorgi V; Pinzani P; Salvianti F; Panelos J; Paglierani M; Janowska A; Grazzini M; Wechsler J; Orlando C; Santucci M; Lotti T; Pazzagli M; Massi D
J Invest Dermatol; 2010 Oct; 130(10):2440-7. PubMed ID: 20535130
[TBL] [Abstract][Full Text] [Related]
39. Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma.
Palmieri G; Satriano SM; Budroni M; Cossu A; Tanda F; Canzanella S; Caracò C; Simeone E; Daponte A; Mozzillo N; Comella G; Castello G; Ascierto PA
BMC Cancer; 2006 Nov; 6():266. PubMed ID: 17107608
[TBL] [Abstract][Full Text] [Related]
40. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.
Palmieri G; Strazzullo M; Ascierto PA; Satriano SM; Daponte A; Castello G
J Clin Oncol; 1999 Jan; 17(1):304-11. PubMed ID: 10458247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]